| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18014 R75992 |
Kernizan (Lamotrigine) (Bipolar disorder), 2024 | Neonatal Intensive Care Unit admission | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 1.18 [0.34;4.06] C | 4/13 38/139 | 42 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15218 R62395 |
Bromley (Lamotrigine) (Epilepsy), 2023 | Neonatal special care admission | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.87 [1.09;7.52] C | 20/106 6/80 | 26 | 106 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12611 R47529 |
Van Marter (Lamotrigine) (Controls unexposed, disease free), 2021 | Need for special care nursery or neonatal intensive care unit (NICU) admission | at least 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
1.25 [0.56;2.74] C excluded (control group) |
16/102 13/100 | 29 | 102 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12613 R47541 |
Van Marter (Lamotrigine) (Controls unexposed, sick), 2021 | Need for special care nursery or neonatal intensive care unit (NICU) admission | at least 1st trimester excluded | prospective cohort | unexposed, sick | Adjustment: No |
1.12 [0.23;5.47] C excluded (exposition period) |
16/102 2/14 | 18 | 102 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8904 R30083 |
Aydin (Lamotrigine), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 4.00 [0.45;35.79] C | 2/7 2/22 | 4 | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8902 R30056 |
Artama (Lamotrigine) (Controls unexposed, disease free), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.97 [1.26;3.08] excluded (control group) |
24/154 49,612/689,482 | 49,636 | 154 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8903 R30068 |
Artama (Lamotrigine) (Controls unexposed, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.38 [0.55;3.47] | 24/154 152/1,708 | 176 | 154 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.85 [1.05;3.25] | 248 | 280 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Lamotrigine) (Bipolar disorder; 2: Lamotrigine) (Epilepsy; 3: Lamotrigine; 4: Lamotrigine) (Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 8902, 12611